Trial Profile
Phase IV study of safety and efficacy of docetaxel in combination with prednisone in advanced hormone refractory prostate cancer treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aventis Pharma; Sanofi
- 27 May 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-001873-91).
- 21 Apr 2008 The expected completion date for this trial is now 1 Oct 2007.
- 15 Apr 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.